LCK JNK 1 LLC takes 6.33% stake in Scinai Immunotherapeutics (SCNI)
Rhea-AI Filing Summary
LCK JNK 1 LLC reports beneficial ownership of 317,366 American Depository Shares (ADS), representing 6.33% of the class of ADS of Scinai Immunotherapeutics Ltd.
The filing shows the ADS class is structured as one ADS = 4,000 ordinary shares. The filing lists sole voting and dispositive power over 317,366 ADS. The document is signed by Richard J. Kertzman as Sole Member on 06/18/2026 and references 04/27/2026 in the cover area.
Positive
- None.
Negative
- None.
Insights
Entity reports a substantial passive stake of 6.33% in SCNI ADS.
The filing amends prior Schedule 13 information to show 317,366 ADS beneficially owned, with sole voting and dispositive power attributed to LCK JNK 1 LLC. The ADS ratio is disclosed as 1 ADS = 4,000 ordinary shares, which clarifies the instrument type held.
Ownership at 6.33% can be a notable disclosure threshold for shareholder reporting; subsequent filings or changes in holdings would appear in future amendments.
Key Figures
Key Terms
beneficially owned regulatory
Schedule 13G/A regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.